This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Makris K, Spanou L. Acute kidney injury: Definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37(2):85-98. PMid:28303073Search in Google Scholar
Magno AL, Herat LY, Carnagarin R, Schlaich MP, Matthews VB. Current knowledge of IL-6 cytokine family members in acute and chronic kidney disease. Biomedicines. 2019;7(1):19. https://doi.org/10.3390/biomedicines7010019 PMid:30871285Search in Google Scholar
Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF. Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol. 2009;296(4):F875-83. https://doi.org/10.1152/ajprenal.90633.2008 PMid:19158344Search in Google Scholar
Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008;19(6):1106-15. https://doi.org/10.1681/ASN.2007070744 PMid:18337485Search in Google Scholar
Gong Y, Yan X, Sun X, Chen T, Liu Y, Cao J. Oncostatin M Is a prognostic biomarker and inflammatory mediator for sepsis. J Infect Dis. 2020;221(12):1989-98. https://doi.org/10.1093/infdis/jiaa009 PMid:31930328Search in Google Scholar
West NR, Hegazy AN, Owens BM, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579-89. https://doi.org/10.1038/nm.4307 PMid:28368383Search in Google Scholar
O’Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: An interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy. 2003;33(8):1026-32. https://doi.org/10.1046/j.1365-2222.2003.01714.x PMid:12911774Search in Google Scholar
Midhuna K, Adole PS, Vinod KV, Balamurugan N. Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus-a pilot study. Diabetes Metab Syndr. 2020;14(5):1087-92. https://doi.org/10.1016/j.dsx.2020.06.026 PMid: 32652496Search in Google Scholar
Hoste EA, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607-25. https://doi.org/10.1038/s41581-018-0052-0 PMid:30135570Search in Google Scholar
Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136(3):737-46.e4. https://doi.org/10.1016/j.jaci.2015.01.043 PMid:25840724Search in Google Scholar
Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 2012;11(4):161-71. https://doi.org/10.3233/CBM-2012-00276 PMid:23144154Search in Google Scholar
Den Hoedt CH, Bots ML, Grooteman MP, Van Der Weerd NC, Mazairac AH, Penne EL, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int. 2014;86(2):423-32. https://doi.org/10.1038/ki.2014.9 PMid:24552852Search in Google Scholar
Nakada TA, Oda S, Matsuda KI, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med. 2008;14(5):257-63. https://doi.org/10.2119/2007-00108.Nakada PMid:18327291Search in Google Scholar
